Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Richter, S; Polychronidis, G; Gotthardt, DN; Houben, P; Giese, T; Sander, A; Dörr-Harim, C; Diener, MK; Schemmer, P.
Effect of delayed CNI-based immunosuppression with Advagraf® on liver function after MELD-based liver transplantation [IMUTECT].
BMC Surg. 2014; 14(6):64-64
Doi: 10.1186/1471-2482-14-64
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Schemmer Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- MELD-based allocation for liver transplantation follows the "sickest-patient-first" strategy. The latter patients present with both, decreased immune competence and poor kidney function which is further impaired by immunosuppressants. In this prospective observational study, 50 patients with de novo low-dose standard Advagraf®-based immunosuppression consisting of Advagraf®, Mycophenolat-mofetil and Corticosteroids after liver transplantation will be evaluated. Advagraf® trough levels of 7-10 μg/l will be reached at the end of the first postoperative week. Immunostatus, infectious complications, graft and kidney function are compared between patients with a pretransplant calculated MELD-score of ≤20 and >20. Each group comprises of 25 consecutive patients. Prior to liver transplantation and on the postoperative days 1, 3 and 7, the patients' graft function (LiMAx test) will be evaluated. On the postoperative days 3, 5 and 7 the patients' immune status will be evaluated by the measurement of their monocytic HLA-DR status.Infectious complications (CMV-reactivation, wound infection, urinary tract infection, and pneumonia), graft- and kidney function will be analysed on day 0, within the first week, and 1, 3, 6, 9 and 12 months after liver transplantation. This study was designed to assess the effect of a standard low-dose Calcineurin inhibitor-based immunosuppression regime with Advagraf® on the rate of infectious complications, graft and renal function after liver transplantation. The trial is registered at "Clinical Trials" (http://www.clinicaltrials.gov), NCT01781195.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Dose-Response Relationship, Drug -
- Drug Therapy, Combination -
- Female -
- Follow-Up Studies -
- Glucocorticoids - administration & dosage
- Glucocorticoids - therapeutic use
- Graft Rejection - immunology
- Graft Rejection - prevention & control
- Humans -
- Immunosuppression - methods
- Immunosuppressive Agents - administration & dosage
- Immunosuppressive Agents - therapeutic use
- Liver Transplantation -
- Male -
- Middle Aged -
- Mycophenolic Acid - administration & dosage
- Mycophenolic Acid - analogs & derivatives
- Mycophenolic Acid - therapeutic use
- Prospective Studies -
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Advagraf (R)
- Prospective observational study
- MELD-score
- Liver function
- LiMAx test
- Infection rate
- HLA-DR status
- Immunostatus